Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Grand Pharmaceutical Group Limited ( (HK:0512) ) just unveiled an update.
Grand Pharmaceutical Group Limited announced the successful completion of Phase II clinical trials for its innovative traditional Chinese medicine, GPN01360, aimed at treating depression. The trial demonstrated significant efficacy and safety, marking a milestone in the company’s efforts to expand its Chinese patent medicine offerings. This development positions the company to provide a novel treatment option for depression, a major global health issue with significant unmet clinical needs.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a major integrated enterprise in China focusing on the research, development, production, and sales of ENT (Ear, Nose, and Throat) drugs. The company is known for its extensive product pipeline, covering various treatment areas such as ophthalmology, otolaryngology, and stomatology, with products ranging from prescription drugs to medical devices. The group is strategically expanding its Chinese patent medicine business to address chronic diseases, leveraging its expertise in traditional Chinese medicine (TCM).
Average Trading Volume: 7,431,799
Technical Sentiment Signal: Buy
Current Market Cap: HK$28.96B
For an in-depth examination of 0512 stock, go to TipRanks’ Overview page.